Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.
作者信息
Weatherald Jason, Moutchia Jude, Al-Naamani Nadine, McClelland Robyn L, Ventetuolo Corey E, Palevsky Harold I, Harhay Michael O, Kawut Steven M
机构信息
Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Department of Biostatistics, Epidemiology, and Informatics and.
出版信息
Am J Respir Crit Care Med. 2023 Dec 1;208(11):1231-1234. doi: 10.1164/rccm.202305-0800LE.
Abstract
摘要
相似文献
1
Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.肺动脉高压临床试验中的获胜统计数据。
Am J Respir Crit Care Med. 2023 Dec 1;208(11):1231-1234. doi: 10.1164/rccm.202305-0800LE.
2
Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No.反对观点：初始三联联合疗法应成为肺动脉高压的标准治疗方案吗？不应该。
Chest. 2024 Mar;165(3):494-496. doi: 10.1016/j.chest.2023.07.4229.
3
POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.观点：初始三联联合疗法应成为肺动脉高压的标准治疗方案吗？ 应该。
Chest. 2024 Mar;165(3):492-494. doi: 10.1016/j.chest.2023.10.001.
4
Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.风险算法在肺动脉高压临床试验中的富集效益。
Am J Respir Crit Care Med. 2021 Mar 15;203(6):726-736. doi: 10.1164/rccm.202002-0357OC.
5
Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension.依前列醇和曲前列尼尔：对肺动脉高压患者调节性T细胞生成的不同影响。
Am J Respir Crit Care Med. 2023 Dec 1;208(11):1248. doi: 10.1164/rccm.202308-1347LE.
6
Treatment of idiopathic/hereditary pulmonary arterial hypertension.特发性/遗传性肺动脉高压的治疗
J Cardiol. 2014 Oct;64(4):243-9. doi: 10.1016/j.jjcc.2014.06.009. Epub 2014 Jul 28.
7
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.儿童肺动脉高压药物治疗的机遇与挑战。
Pediatr Pulmonol. 2021 Mar;56(3):593-613. doi: 10.1002/ppul.25101. Epub 2020 Oct 12.
8
Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension.曲前列尼尔治疗可降低儿科肺动脉高压患者循环血小板微囊泡及其促凝活性。
Pediatr Pulmonol. 2019 Jan;54(1):66-72. doi: 10.1002/ppul.24190. Epub 2018 Nov 28.
9
Clinical Response to Pulmonary Arterial Hypertension Treatment Does Not Depend on Pulmonary Arterial Wedge Pressure: A Meta-Analysis Using Individual Participant Data from Randomized Clinical Trials.肺动脉高压治疗的临床反应不取决于肺动脉楔压：一项使用随机临床试验个体参与者数据的荟萃分析
Am J Respir Crit Care Med. 2024 Sep 15;210(6):844-847. doi: 10.1164/rccm.202403-0612RL.
10
Could pulmonary arterial hypertension-specific agents be an option for Takayasu's arteritis related pulmonary hypertension?肺动脉高压特异性药物能否成为大动脉炎相关肺动脉高压的一种治疗选择？
Clin Exp Rheumatol. 2024 Apr;42(4):940-941. doi: 10.55563/clinexprheumatol/03vsp0. Epub 2023 Jul 5.
引用本文的文献
1
Win Ratio in Biomedical Science: A Bibliometric Analysis.生物医学科学中的胜率：文献计量分析
CJC Open. 2025 May 21;7(8):1097-1107. doi: 10.1016/j.cjco.2025.05.006. eCollection 2025 Aug.
2
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.肺动脉高压的临床试验设计、终点和新兴疗法。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01205-2024. Print 2024 Oct.
本文引用的文献
1
Patients' perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy.患者对肺动脉高压治疗临床试验结果的看法。
Thorax. 2023 Jul;78(7):721-725. doi: 10.1136/thorax-2022-219490. Epub 2023 May 4.
2
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.索他洛尔治疗肺动脉高压的3期试验
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
3
Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.肺动脉高压患者 6 分钟步行距离的最小临床重要差异。
Am J Respir Crit Care Med. 2023 Apr 15;207(8):1070-1079. doi: 10.1164/rccm.202208-1547OC.
4
The evolving landscape of pulmonary arterial hypertension clinical trials.肺动脉高压临床试验的演变格局。
Lancet. 2022 Nov 26;400(10366):1884-1898. doi: 10.1016/S0140-6736(22)01601-4.
5
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.肺动脉高压随机临床试验中的基线性别差异。
Ann Am Thorac Soc. 2023 Jan;20(1):58-66. doi: 10.1513/AnnalsATS.202203-207OC.
6
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.赢率（赢率比、赢率优势和净效益）可以相互补充，以显示对生存时间结局的治疗效果的强度。
Pharm Stat. 2023 Jan;22(1):20-33. doi: 10.1002/pst.2251. Epub 2022 Jun 27.
7
BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.肺动脉高压患者的体重指数与治疗反应：一项荟萃分析。
Chest. 2022 Aug;162(2):436-447. doi: 10.1016/j.chest.2022.02.041. Epub 2022 Mar 3.
8
Sample size formula for a win ratio endpoint.赢率结局的样本量公式。
Stat Med. 2022 Mar 15;41(6):950-963. doi: 10.1002/sim.9297. Epub 2022 Jan 27.
9
Win odds: An adaptation of the win ratio to include ties.胜率：对胜率的一种调整，包括平局。
Stat Med. 2021 Jun 30;40(14):3367-3384. doi: 10.1002/sim.8967. Epub 2021 Apr 16.
10
Adjusting win statistics for dependent censoring.调整依赖删失的赢率统计。
Pharm Stat. 2021 May;20(3):440-450. doi: 10.1002/pst.2086. Epub 2020 Nov 28.
Zotero 插件